PreTel’s area sensor uterine electromyography (uEMG) monitoring solves the inability of existing technology to accurately identify independent contraction activity of individual regions of the uterus. Identification of this regional activity allows for improved care in the preterm labor patient, managing the progress of labor at time of delivery, and safety to the admiration of induction therapy.
These improvements will avoid unnecessary C-Section deliveries, post-delivery maternal hemorrhage, and expensive neonatal intensive care nursery stays.
PreTel pregnancy monitoring systems integrate the reporting of fetal heart rate (FHR), maternal heart rate (MHR), contraction activity and individual region activity into a portable patient wearable device. System solutions include interface to existing hospital central monitoring hardware and cloud access for home monitoring applications.
The PreTel pregnancy monitoring system improves both maternal and neonatal outcomes in the labor and delivery department, across hospital systems and throughout integrated health care networks.
Pregnancy monitoring impacts 3.7 Million births (US) improving both maternal and neonatal outcomes.
Wearable Area Sensor technology provides the determination of the amount of individual regions of the uterus that make up each contraction. This unique uterine EMG technique is combined with fetal and maternal ECG monitoring in the PreTel Juno Pregnancy Monitoring System. The PreTel Juno Pregnancy Monitoring Systems not commercially available for sale.
Chattanooga, TN —January 15, 2021 - PreTel, Inc., a rapidly emerging private Femtech company focusing on improving the lives of expectant mothers and women in labor, has appointed Mark A. Samuels as Executive Chairman of its Board of Directors.
Mr. Samuels has extensive experience in the medical device sector and served as President and CEO of OBMedical Company from 2016 to 2018 prior to its acquisition by Phillips Medical. OBMedical’s products included an FDA cleared, wireless electrode-based maternal-fetal monitor for measuring labor contractions and fetal heart rate. Mr. Samuels previously led the development and commercialization of various medical device technologies across women’s health and maternal-infant care for cancer detection, breast cancer imaging and serum bilirubin detection.
Mr. Samuels will be working with PreTel’s CEO, Marc Finch, and founder Roger Young, MD, PhD, to guide the continued development of targeted uterine myography monitoring and intelligent analysis to improve pregnancy, labor and delivery outcomes.
“I believe PreTel represents a significant opportunity to improve the health and safety of mothers and babies during pregnancy and labor using its advanced technology platform aimed at predicting labor, monitoring the progress of labor and adjusting Pitocin drug delivery,” said Mr. Samuels. “About 40% of all women in the United States experience false labor at a very high financial and emotional cost. PreTel’s technology has the potential to significantly improve the ability of healthcare professionals to respond appropriately.”
“Mark’s addition to the PreTel team comes at a critical time as we prepare to convert our proprietary system of uterine myography signal detection and intelligent analysis for preterm labor diagnosis and maternal and fetal safety during labor and delivery into bedside monitoring. His successes in the launch of new medical technology solutions into the health care system and understanding of the maternal fetal care delivery space will be instrumental in establishing key partnerships to ensure our success,” said Marc Finch, CEO.
PreTel, Inc. is a private, US-based Femtech company recognized for its innovative work in novel uterine electromyography (uEMG) signal detection and intelligent analysis for the large maternal-fetal medicine markets of both remote and hospital care. The company’s proprietary “Area Sensor” platform is being developed for early warning monitoring for pregnancies that may result in spontaneous preterm birth, labor and delivery care, and the personalized dosing of Pitocin during labor induction to optimize pregnancy care of both mother and baby. For more information, please visit www.pretelhealth.com.
Corporate Contact: Marc Finch, 423.243.3460, firstname.lastname@example.org
We are a team of professionals, dedicated to improving the health of women and babies by expanding their options with innovative medical devices that provide significant clinical impact.